These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24331668)

  • 1. Alpha/beta ratio for normal lung tissue as estimated from lung cancer patients treated with stereotactic body and conventionally fractionated radiation therapy.
    Scheenstra AE; Rossi MM; Belderbos JS; Damen EM; Lebesque JV; Sonke JJ
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):224-8. PubMed ID: 24331668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
    Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Xiao Y; Grills IS
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1074-81. PubMed ID: 23154077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy.
    Park C; Papiez L; Zhang S; Story M; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):847-52. PubMed ID: 18262098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Koshy M; Malik R; Weichselbaum RR; Sher DJ
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):344-50. PubMed ID: 25636759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy.
    Borst GR; Ishikawa M; Nijkamp J; Hauptmann M; Shirato H; Onimaru R; van den Heuvel MM; Belderbos J; Lebesque JV; Sonke JJ
    Radiother Oncol; 2009 Jun; 91(3):307-13. PubMed ID: 19321217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Local dose-effect relations for lung perfusion post stereotactic body radiotherapy.
    Scheenstra AE; Rossi MM; Belderbos JS; Damen EM; Lebesque JV; Sonke JJ
    Radiother Oncol; 2013 Jun; 107(3):398-402. PubMed ID: 23623727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
    Stephans KL; Djemil T; Diaconu C; Reddy CA; Xia P; Woody NM; Greskovich J; Makkar V; Videtic GM
    Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):197-202. PubMed ID: 25015204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer.
    Hiraoka M; Matsuo Y; Nagata Y
    Cancer Radiother; 2007; 11(1-2):32-5. PubMed ID: 17158081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A challenge to traditional radiation oncology.
    Fowler JF; Tomé WA; Fenwick JD; Mehta MP
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1241-56. PubMed ID: 15519797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton arc reduces range uncertainty effects and improves conformality compared with photon volumetric modulated arc therapy in stereotactic body radiation therapy for non-small cell lung cancer.
    Seco J; Gu G; Marcelos T; Kooy H; Willers H
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):188-94. PubMed ID: 23920395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: a prospective study.
    Feddock J; Arnold SM; Shelton BJ; Sinha P; Conrad G; Chen L; Rinehart J; McGarry RC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1325-31. PubMed ID: 23265574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of biological effective dose-based fractionated stereotactic radiation therapy for metastatic brain tumors from non-small cell lung cancer.
    Matsuyama T; Kogo K; Oya N
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):984-90. PubMed ID: 23092725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).
    Dunlap NE; Larner JM; Read PW; Kozower BD; Lau CL; Sheng K; Jones DR
    J Thorac Cardiovasc Surg; 2010 Sep; 140(3):583-9. PubMed ID: 20478576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction.
    Wennberg BM; Baumann P; Gagliardi G; Nyman J; Drugge N; Hoyer M; Traberg A; Nilsson K; Morhed E; Ekberg L; Wittgren L; Lund JÅ; Levin N; Sederholm C; Lewensohn R; Lax I
    Acta Oncol; 2011 May; 50(4):518-27. PubMed ID: 21198416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting chest wall pain from lung stereotactic body radiotherapy for different fractionation schemes.
    Woody NM; Videtic GM; Stephans KL; Djemil T; Kim Y; Xia P
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):427-34. PubMed ID: 22197087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computed 88% TCP dose for SBRT of NSCLC from tumour hypoxia modelling.
    Ruggieri R; Stavreva N; Naccarato S; Stavrev P
    Phys Med Biol; 2013 Jul; 58(13):4611-20. PubMed ID: 23771131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosimetric predictors of radiation-induced lung injury in stereotactic body radiation therapy.
    Ricardi U; Filippi AR; Guarneri A; Giglioli FR; Mantovani C; Fiandra C; Anglesio S; Ragona R
    Acta Oncol; 2009; 48(4):571-7. PubMed ID: 19031164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: the pattern of failure is distant.
    Bradley JD; El Naqa I; Drzymala RE; Trovo M; Jones G; Denning MD
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(4):1146-50. PubMed ID: 19800181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.